Skip to content

Study of the efficacy of memantine in metastatic colon cance

Study of the efficacy of memantine as adjunctive therapy with chemotherapy regimen in metastatic colon cancer: A pilot randomized clinical trial

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210819052230N1
Enrollment
50
Registered
2022-01-29
Start date
2022-01-10
Completion date
Unknown
Last updated
2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic colon cancer. Malignant neoplasm of colon

Interventions

Intervention 1: Intervention group: Standard chemotherapy drugs for colon cancer + memantine Memantine, which is our intervention, will be administered ora

Sponsors

Oroumia University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: All patients over 18 years of age with metastatic colon cancer

Exclusion criteria

Exclusion criteria: Severe renal failure Liver failure (more than 5-fold increase in liver enzymes) History of memantine allergy History of seizures Cardiovascular disease Eye diseases Concomitant use of drugs that alter the pH of the urine.

Design outcomes

Primary

MeasureTime frame
Quality of life in patient with colon cancer. Timepoint: Beginning and end of the study (third month). Method of measurement: QLQ-C30 Questionnaire.;The size of tumor in patients with colon cancer. Timepoint: Beginning and end of the study (third month). Method of measurement: CT scan.

Secondary

MeasureTime frame
Vascular endothelial growth factor (VEGF). Timepoint: Beginning and end of the study (third month). Method of measurement: ELISA kit.;Carcinoembryonic Antigen (CEA). Timepoint: Beginning and end of the study (third month). Method of measurement: ELISA kit.;Body Mass Index (BMI). Timepoint: Beginning and end of the study (third month). Method of measurement: weight kg/height m2.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Hamid Soraya

Oroumia University of Medical Sciences

hamid_soraya2000@yahoo.com+98 44 3275 4996

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026